Hypotension from afatinib in epidermal growth factor receptor-mutated non-small cell lung cancer: a case report and literature review

被引：2
|
作者：
Tang, Zhiwei [1 ]
Ji, XiuHai [2 ]
Zhou, Guanghui [1 ]
Chen, Ruhua [1 ]
Fen, Yan [1 ]
Ding, Hui [1 ]
机构：
[1] Jiangsu Univ, Affiliated Yixing Peoples Hosp, Dept Pulm & Crit Care Med, Yixing, Peoples R China
[2] Affiliated Taicang Hosp Tradit Chinese Med, Dept Oncol, Taicang, Peoples R China
来源：
ANTI-CANCER DRUGS | 2022年 / 33卷 / 01期
关键词：
afatinib; epidermal growth factor receptor; hypotension; lung cancer;
D O I：
10.1097/CAD.0000000000001244
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Side effects of afatinib are a problem in patients with advanced non-small cell lung cancer (NSCLC). However, little is known about the occurrence of afatinib-induced hypotension. An 81-year-old man with NSCLC had an epidermal growth factor receptor-positive genotype with the p.L861Q mutation in exon 21. He was administered afatinib (40 mg/day) as anticancer therapy. Hypotension occurred twice after afatinib initiation. He suffered from dizziness and nausea. Blood pressure gradually returned to normal after afatinib cessation. Clinicians should be aware of hypotension in patients with NSCLC after afatinib initiation.
引用
收藏
页码：E840 / E841
页数：2
相关论文
共 50 条
  • [21] Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors
    Vaca, Silvia Daniela
    Connolly, Ian David
    Ho, Clement
    Neal, Joel
    Gephart, Melanie Hayden
    NEUROSURGERY, 2018, 82 (01) : E6 - E14
  • [22] A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
    Lee, Chung-Shien
    Sharma, Sandhya
    Miao, Emily
    Mensah, Cheryl
    Sullivan, Kevin
    Seetharamu, Nagashree
    LUNG CANCER-TARGETS AND THERAPY, 2020, 11 : 73 - 103
  • [23] Prognostic outcome of treatment modalities for epidermal growth factor receptor-mutated advanced lung cancer
    Jang, Seung Hun
    Lee, Dong Yoon
    Jeong, Jihyeon
    Choi, Won-Il
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2022, 37 (04) : 811 - 820
  • [24] The optimal therapy strategy for epidermal growth factor receptor-mutated non-small cell lung cancer patients with brain metastasis: A real-world study from Taiwan
    Cheng, Wen-Chien
    Shen, Yi-Cheng
    Chien, Chun-Ru
    Liao, Wei-Chih
    Chen, Chia-Hung
    Hsia, Te-Chun
    Tu, Chih-Yeh
    Chen, Hung-Jen
    THORACIC CANCER, 2022, 13 (10) : 1505 - 1512
  • [25] Epidermal growth factor receptor-mutated lung carcinomas with insufficient response to epidermal growth factor receptor inhibitors
    Moiseenko, Fedor
    Kuligina, Ekaterina
    Elsakova, Ekaterina
    Imyanitov, Evgeny
    FUTURE ONCOLOGY, 2024, 20 (31) : 2397 - 2407
  • [26] Targeted therapy for the treatment of advanced non-small cell lung cancer - A review of the epidermal growth factor receptor antagonists
    Silvestri, GA
    Rivera, MP
    CHEST, 2005, 128 (06) : 3975 - 3984
  • [27] Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status
    Xu, Haiyan
    Chen, Hengqi
    Kong, Jianxin
    Zhang, Ye
    Liu, Shan
    Yang, Guangjian
    Yang, Lu
    Wang, Yan
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (11)
  • [28] Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation
    Bollinger, Meredith K.
    Agnew, Amanda S.
    Mascara, Gerard P.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (05) : 379 - 388
  • [29] Cost-effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor-mutated non-small-cell lung cancer
    Li, Wenqian
    Qian, Lei
    Li, Wei
    Chen, Xiao
    He, Hua
    Tian, Huimin
    Zhao, Yuguang
    Wang, Xu
    Cui, Jiuwei
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (04)
  • [30] Relationship between Epidermal Growth Factor Receptor Mutations and Adverse Events in Non-Small Cell Lung Cancer Patients treated with Afatinib
    Yamashita, Sayaka
    Tanaka, Hiroaki
    Tatsumichi, Takakiyo
    Yamaguchi, Kazunori
    Tai, Tatsuya
    Suzuki, Kiyo
    Motoki, Takahiro
    Houchi, Hitoshi
    Kosaka, Shinji
    JOURNAL OF MEDICAL INVESTIGATION, 2021, 68 (1-2) : 125 - 128
12345